| abstract |
A disubstituted piperazine compound having formula (I) wherein R1 is halogen, methoxy, C1-6-alkyl or trifluoromethyl, and R2 is methyl or substituted C1-8-alkyl, C3-8-alkenyl or C3-8-cycloalkyl, where substituents may be hydroxy-, keto- or oximino-groups in any position leading to a stable tertiary amine; or R2 is a straight or branched C1-8-alkyl or C3-8-alkenyl, which in any position may be substituted as above, but is terminally substituted with one of the following groups: cyano, optionally C1-4-alkoxy-substituted C1-4-alkoxy, dimethoxy, optionally substituted phenoxy, phosphonic acid, thienyl, furyl, oxazoline, isoxazole, oxadiazole, where the optional substitution is represented by C1-6-alkyl or phenyl, provided that when cyano is the only substituent in R2, R2 must contain at least four carbon atoms, and pharmaceutically acceptable acid addition salts thereof. The compounds are useful in the treatment of mental disorders in which a dopaminergic deficit is implicated. |